(Q34410241)

2 August 2017

title

Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients (English)

1 reference

2 August 2017

0 references

1 reference

P Ruszniewski

1

1 reference

2 August 2017

M Ducreux

2

1 reference

2 August 2017

J A Chayvialle

3

1 reference

2 August 2017

J Blumberg

4

1 reference

2 August 2017

D Cloarec

5

1 reference

2 August 2017

H Michel

6

1 reference

2 August 2017

J M Raymond

7

1 reference

2 August 2017

J L Dupas

8

1 reference

2 August 2017

H Gouerou

9

1 reference

2 August 2017

R Jian

10

1 reference

2 August 2017

E Genestin

11

1 reference

2 August 2017

P Bernades

12

1 reference

2 August 2017

P Rougier

13

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 August 1996

1 reference

2 August 2017

1 reference

2 August 2017

volume

39

1 reference

2 August 2017

issue

2

1 reference

2 August 2017

page(s)

279-283

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1383312

2 August 2017

1 reference

Use of octreotide acetate for control of symptoms in patients with islet cell tumors

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1383312

Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1383312

Somatostatin, gastrointestinal peptides, and the carcinoid syndrome

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1383312

Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1383312

NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1383312

A study of cyproheptadine in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndrome

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1383312

Carcinoid TumorsAn analysis of 2837 cases

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1383312

Use of somatostatin analog in management of carcinoid syndrome

6 July 2018

1 reference

12 December 2020

Therapy of the malignant carcinoid syndrome

1 reference

12 December 2020

Sandostatin and Carcinoid Tumours in France: Experience in the Lyon Area

1 reference

12 December 2020

Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon

1 reference

12 December 2020

The role of somatostatin analogs in the treatment of endocrine gastrointestinal tumors

1 reference

12 December 2020

Gallstones during octreotide therapy

1 reference

12 December 2020

Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide

1 reference

12 December 2020

Treatment of the carcinoid syndrome with a depot formulation of the somatostatin analogue lanreotide

1 reference

12 December 2020

Serotonin now: clinical implications of inhibiting its synthesis with para-chlorophenylalanine

1 reference

12 December 2020

The carcinoid flush. Provocation by pentagastrin and inhibition by somatostatin

1 reference

12 December 2020

Long-term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases

1 reference

12 December 2020

Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue

1 reference

12 December 2020

Clinical and hormonal effects of a long-acting somatostatin analogue in pancreatic endocrine tumors and in carcinoid syndrome

1 reference

12 December 2020

Effects of the somatostatin analog BIM 23014 on the secretion of growth hormone, thyrotropin, and digestive peptides in normal men

1 reference

12 December 2020

Identifiers

DOI

10.1136/GUT.39.2.279

1 reference

2 August 2017

1 reference

2 August 2017

1 reference